Eribulin 1mg Injection

Introduction

Eribulin is a medication that contains the active ingredient Eribulin Mesylate. It is available in the form of an injection and is used for the treatment of certain types of cancer.

Uses

Eribulin is primarily prescribed for the treatment of metastatic breast cancer. It is used in patients who have already received at least two prior chemotherapy regimens for their advanced disease. It can also be used for the treatment of liposarcoma, a type of soft tissue sarcoma, in patients who have previously received chemotherapy.

Dosage and Administration

Eribulin is administered intravenously by a healthcare professional. The recommended dosage is based on the patient’s body surface area and is typically given on specific days of a 21-day treatment cycle. Your healthcare provider will determine the appropriate dosage and schedule for your specific condition.

Mechanism of Action

Eribulin Mesylate, the active ingredient in Eribulin, works by inhibiting the growth of cancer cells. It belongs to a class of medications called microtubule inhibitors. It disrupts the microtubule network within cancer cells, preventing their proper function and ultimately leading to cell death.

Side Effects

Common side effects may include fatigue, nausea, vomiting, constipation, diarrhea, hair loss, and a decrease in appetite. Report these side effects to your healthcare provider, as they can provide guidance on managing them.

Serious side effects may include a decrease in white blood cell count, which can increase the risk of infection, as well as a decrease in platelet count, which can lead to bleeding. Contact your healthcare provider immediately if you experience signs of infection such as fever, chills, or persistent sore throat, or if you have unusual bleeding or bruising.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including over-the-counter drugs, herbal supplements, and vitamins. Certain medications may interact with Eribulin, potentially affecting its effectiveness or increasing the risk of side effects. Some medications that may interact with Eribulin include strong CYP3A4 inhibitors, such as ketoconazole or clarithromycin.

Precautions

Before starting treatment with Eribulin, inform your healthcare provider about any medical conditions you have, including liver or kidney problems. This medication should be used with caution in patients with pre-existing heart conditions, as it may cause changes in heart rhythm.

Eribulin is not recommended for use during pregnancy. It may cause harm to the unborn baby. Use effective contraception during treatment and for a certain period after the last dose. Breastfeeding should be avoided while receiving Eribulin.

Storage

Patient Tips

• Follow the dosage instructions provided by your healthcare provider.
• Attend all scheduled appointments for administration of Eribulin.
• Report any side effects to your healthcare provider promptly.
• Use effective contraception during treatment and for a certain period after the last dose if you are of childbearing potential.
• Store the medication properly in the refrigerator and do not freeze it.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Eribulin (Drugs.com) [Accessed 13 Jun. 2024] (online) Available at:
• Drugs Approved for Soft Tissue Sarcoma (National Cancer Institute) [Accessed 16 Jun. 2024] (online) Available at:
• Jain S, Vahdat LT. Eribulin mesylate. Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. [Accessed 24 Jun. 2024] Available at:
• A to Z List of Cancer Drugs (National Cancer Institute) [Accessed 20 Jun. 2024] (online) Available at: